March 27, 2017
Otsuka Pharmaceutical and its Danish partner Lundbeck A/S said on March 24 that the European Medicines Agency (EMA) has accepted their antipsychotic brexpiprazole for review for the treatment of schizophrenia in adults. The EMA is expected to complete its review...read more